Oculis Holding AG (OCS) Enterprise Value (2021 - 2026)
Oculis Holding AG (OCS) posted quarterly Enterprise Value of -$283.5 million for Q1 2026, down 40.12% year-over-year from -$473.5 million in Q1 2025, and down 6.39% quarter-over-quarter from -$266.5 million in Q4 2025.
Oculis Holding AG (OCS) Enterprise Value (2021 - 2026) Analysis & Trends
Oculis Holding AG's Enterprise Value history runs 6 years deep, the most recent figure standing at -$283.5 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 40.12% year-over-year to -$283.5 million; the TTM figure through Mar 2026 stood at -$283.5 million (down 40.12% YoY), while the FY2025 annual figure was -$256.9 million, down 129.09% from the prior year.
- Enterprise Value for Q1 2026 stood at -$283.5 million, down from -$266.5 million in the prior quarter.
- The five-year high for Enterprise Value was $51.1 million in Q3 2023, with the low at -$283.5 million in Q1 2026.
- The 5-year median for Enterprise Value is -$121.7 million (2024), against an average of -$115.5 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value surged 186.92% in 2023, then tumbled 730.86% in 2024.
- Oculis Holding AG's Enterprise Value stood at -$20.5 million in 2022, then jumped by 186.92% to $17.9 million in 2023, then slumped by 730.86% to -$112.6 million in 2024, then slumped by 136.64% to -$266.5 million in 2025, then retreated by 6.39% to -$283.5 million in 2026.
- Business Quant data shows OCS's Enterprise Value at -$283.5 million in Q1 2026, -$266.5 million in Q4 2025, and -$181.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - | -288.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -288.88 Mn |
| Mar 31, 2026 | -283.54 Mn |
| Dec 31, 2025 | -266.52 Mn |
| Sep 30, 2025 | -181.49 Mn |
| Jun 30, 2025 | -193.62 Mn |
| Mar 31, 2025 | -202.35 Mn |
| Dec 31, 2024 | -112.63 Mn |
| Sep 30, 2024 | -121.74 Mn |
| Jun 30, 2024 | -130.40 Mn |
| Mar 31, 2024 | -91.58 Mn |
| Dec 31, 2023 | 17.85 Mn |
| Sep 30, 2023 | 51.11 Mn |
| Jun 30, 2023 | 33.53 Mn |
| Dec 31, 2022 | -20.54 Mn |
| Dec 31, 2021 | -50.19 Mn |